261 related articles for article (PubMed ID: 37007635)
1. Advances in immunotherapy for cervical cancer.
Grau-Bejar JF; Garcia-Duran C; Garcia-Illescas D; Mirallas O; Oaknin A
Ther Adv Med Oncol; 2023; 15():17588359231163836. PubMed ID: 37007635
[TBL] [Abstract][Full Text] [Related]
2. Advances in immunotherapy in cervical cancer.
Grau JF; Farinas-Madrid L; Garcia-Duran C; Garcia-Illescas D; Oaknin A
Int J Gynecol Cancer; 2023 Mar; 33(3):403-413. PubMed ID: 36878562
[TBL] [Abstract][Full Text] [Related]
3. Management of patients with recurrent/advanced cervical cancer beyond first line platinum regimens: Where do we stand? A literature review.
Boussios S; Seraj E; Zarkavelis G; Petrakis D; Kollas A; Kafantari A; Assi A; Tatsi K; Pavlidis N; Pentheroudakis G
Crit Rev Oncol Hematol; 2016 Dec; 108():164-174. PubMed ID: 27931835
[TBL] [Abstract][Full Text] [Related]
4. The current status of immunotherapy for cervical cancer.
Orbegoso C; Murali K; Banerjee S
Rep Pract Oncol Radiother; 2018; 23(6):580-588. PubMed ID: 30534022
[TBL] [Abstract][Full Text] [Related]
5. A randomized phase III trial of platinum chemotherapy plus paclitaxel with bevacizumab and atezolizumab versus platinum chemotherapy plus paclitaxel and bevacizumab in metastatic (stage IVB), persistent, or recurrent carcinoma of the cervix: the BEATcc study (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030).
Grau JF; Farinas-Madrid L; Oaknin A
Int J Gynecol Cancer; 2020 Jan; 30(1):139-143. PubMed ID: 31645423
[TBL] [Abstract][Full Text] [Related]
6. Advances in immunotherapy for cervical cancer: recent developments and future directions.
Sherer MV; Kotha NV; Williamson C; Mayadev J
Int J Gynecol Cancer; 2022 Mar; 32(3):281-287. PubMed ID: 35256414
[TBL] [Abstract][Full Text] [Related]
7. Recurrent or primary metastatic cervical cancer: current and future treatments.
Gennigens C; Jerusalem G; Lapaille L; De Cuypere M; Streel S; Kridelka F; Ray-Coquard I
ESMO Open; 2022 Oct; 7(5):100579. PubMed ID: 36108558
[TBL] [Abstract][Full Text] [Related]
8. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
9. Targeted treatment options for the management of metastatic/persistent and recurrent cervical cancer.
Mutlu L; Tymon-Rosario J; Harold J; Menderes G
Expert Rev Anticancer Ther; 2022 Jun; 22(6):633-645. PubMed ID: 35533682
[TBL] [Abstract][Full Text] [Related]
10. Current Status of Clinical Trials for Cervical and Uterine Cancer Using Immunotherapy Combined With Radiation.
Dyer BA; Feng CH; Eskander R; Sharabi AB; Mell LK; McHale M; Mayadev JS
Int J Radiat Oncol Biol Phys; 2021 Feb; 109(2):396-412. PubMed ID: 32942005
[TBL] [Abstract][Full Text] [Related]
11. Epidermal growth factor receptor targeted therapy in stages III and IV head and neck cancer.
Cripps C; Winquist E; Devries MC; Stys-Norman D; Gilbert R;
Curr Oncol; 2010 Jun; 17(3):37-48. PubMed ID: 20567625
[TBL] [Abstract][Full Text] [Related]
12. Immune checkpoint inhibitors in head and neck squamous cell carcinoma: A systematic review of phase-3 clinical trials.
Poulose JV; Kainickal CT
World J Clin Oncol; 2022 May; 13(5):388-411. PubMed ID: 35662989
[TBL] [Abstract][Full Text] [Related]
13. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy for Uterine Cervical Cancer.
Kagabu M; Nagasawa T; Fukagawa D; Tomabechi H; Sato S; Shoji T; Baba T
Healthcare (Basel); 2019 Sep; 7(3):. PubMed ID: 31533297
[TBL] [Abstract][Full Text] [Related]
15. Advances in the Management of Recurrent Cervical Cancer: State of the Art and Future Perspectives.
Giudice E; Mirza MR; Lorusso D
Curr Oncol Rep; 2023 Nov; 25(11):1307-1326. PubMed ID: 37870697
[TBL] [Abstract][Full Text] [Related]
16. Targeted Agents in Cervical Cancer: Beyond Bevacizumab.
Marquina G; Manzano A; Casado A
Curr Oncol Rep; 2018 Apr; 20(5):40. PubMed ID: 29611060
[TBL] [Abstract][Full Text] [Related]
17. Nivolumab in chemotherapy-resistant cervical cancer: report of a vulvitis as a novel immune-related adverse event and molecular analysis of a persistent complete response.
Baettig F; Vlajnic T; Vetter M; Glatz K; Hench J; Frank S; Bihl M; Lopez R; Dobbie M; Heinzelmann-Schwarz V; Montavon C
J Immunother Cancer; 2019 Oct; 7(1):281. PubMed ID: 31672171
[TBL] [Abstract][Full Text] [Related]
18. Immune Environment and Immunotherapy in Endometrial Carcinoma and Cervical Tumors.
Lainé A; Gonzalez-Lopez AM; Hasan U; Ohkuma R; Ray-Coquard I
Cancers (Basel); 2023 Mar; 15(7):. PubMed ID: 37046702
[TBL] [Abstract][Full Text] [Related]
19. A 2020 update of anal cancer: the increasing problem in women and expanding treatment landscape.
Lum C; Prenen H; Body A; Lam M; Segelov E
Expert Rev Gastroenterol Hepatol; 2020 Aug; 14(8):665-680. PubMed ID: 32458709
[TBL] [Abstract][Full Text] [Related]
20. Toripalimab combined with concurrent platinum-based Chemoradiotherapy in patients with locally advanced cervical Cancer: an open-label, single-arm, phase II trial.
Chen J; Li C; Cao Y; Zhu L; Zhang B; You J; Hou H; Wang J; Yuan Z
BMC Cancer; 2022 Jul; 22(1):793. PubMed ID: 35854236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
